“CRISPR/Cas9 is a powerful in vivo genome engineering tool that has revolutionised many research areas. At ERS, we are committed to make this technology broadly available. We are very pleased to support genOway’s development with this licence agreement,” said Eric Rhodes, CEO of ERS Genomics (pictured).
“This licence from ERS will broaden our CRISPR IP portfolio, and widen our rodent models offering,” said Alexandre Fraichard, CEO of genOway. “This will ultimately enable us to pursue our mission of providing the scientific community with scientifically highly relevant preclinical models paired with guaranteed freedom to operate, in particular for commercial applications.”
Financial details of the agreement are not disclosed.